Spring 2004 Volume 5, Issue 10
Los Angeles Area Support Group Salutes Leader<br>IMFers Pay Tribute To Janet Johnson
Message from IMF President
On behalf of the International Myeloma Foundation, I would like to thank you for your support and update you on our progress with the IMF’s research project, Bank On A Cure®.
Why Bank On A Cure®?
Every myeloma patient is unique. Treatment should be too.
Treating Multiple Myeloma: The Little Rock Approach
Peripheral blood stem cell (PBSC)-supported high-dose melphalan 200 mg/m2 is now considered standard therapy for patients with symptomatic or progressive myeloma. During the last five years, additional new agents effecting salvage rates of 30% - 50%
The Genetics of Multiple Myeloma
Extensive genetic lesions, both at the chromosome and gene levels, characterize malignant plasma cells. Although most patients present with a large number of malignant plasma cells at diagnosis (up to 1,000 billion malignant cells), chromosomal analy
Drug Resistance: Overcoming Multiple Myeloma Drug Resistance by Inhibiting the Proteasome
There are many difficult hurdles to overcome in the treatment of multiple myeloma, but one of the most important is a phenomenon called drug resistance.
The International Myeloma Foundation (IMF) and Millennium Pharmaceuticals, Inc., of Cambridge, MA, the developer of VELCADE® (bortezomib) for Injection, are collaborating on a national medical education program designed for oncology nurses.
Atiprimod: A New Drug Candidate in Early-Stage Development for Myeloma
Atiprimod has a very interesting history, providing yet another example of a drug candidate that begins its story as a potential treatment for a wholly different disease indication.
Cancer Research and Medicare: Political Pork?
IMF Kicks Off 2004 Seminars with Florida Retreat
In talking with first-time participants as well as those who had attended IMF seminars previously, it is very evident that no matter how many of these wonderful weekends one has been to, there is always new, pertinent information available.